Vanguard Group Inc Galera Therapeutics, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.09 - $0.27 $54,769 - $164,307	-608,547 Reduced 57.58%	448,330 $62,000
Q3 2023 Nov 14, 2023	SELL	$0.17 - $3.0 $63,258 - $1.12 Million	-372,109 Reduced 26.04%	1,056,877 $190,000
Q2 2023 Aug 14, 2023	BUY	$2.5 - $3.42 $906,517 - $1.24 Million	362,607 Added 34.0%	1,428,986 $4.46 Million
Q1 2023 May 15, 2023	BUY	$1.48 - $2.68 $809,777 - $1.47 Million	547,147 Added 105.38%	1,066,379 $2.73 Million
Q4 2022 Feb 10, 2023	BUY	$1.34 - $1.78 $114,216 - $151,720	85,236 Added 19.64%	519,232 $773,000
Q3 2022 Nov 14, 2022	SELL	$1.15 - $2.1 $2,274 - $4,153	-1,978 Reduced 0.45%	433,996 $755,000
Q2 2022 Aug 12, 2022	SELL	$1.24 - $2.39 $1,747 - $3,367	-1,409 Reduced 0.32%	435,974 $567,000
Q1 2022 May 13, 2022	SELL	$2.01 - $4.19 $63,347 - $132,052	-31,516 Reduced 6.72%	437,383 $1.04 Million
Q4 2021 Feb 14, 2022	SELL	$1.27 - $8.28 $16,033 - $104,534	-12,625 Reduced 2.62%	468,899 $2.15 Million
Q2 2021 Aug 13, 2021	BUY	$6.08 - $10.44 $2.93 Million - $5.03 Million	481,524 New	481,524 $4.73 Million

961K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $1.34M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.